- Home
- BHAV vs EQ Comparison
BHAV vs EQ Comparison
Compare BHAV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHAV | EQ |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 140.1M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BHAV | EQ |
|---|---|---|
| Price | $10.05 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 27.2K | ★ 581.4K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $0.76 |
| 52 Week High | $10.05 | $3.54 |
Technical Indicators
Market Signals| Indicator | BHAV | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 29.07 |
| Support Level | $9.98 | $1.05 |
| Resistance Level | $10.05 | $1.71 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 13.04 | 2.42 |
Price Performance
Historical ComparisonAbout BHAV BHAV Acquisition Corp Class A Ordinary Shares
BHAV Acquisition Corp is a blank check company.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.